Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
DE40: Regulatory and diplomatic escalations amid holidays
Novo Nordisk - There Were Risks, Now It's Time for Opportunities.
US OPEN: Renewed optimism at the beginning of the week
Nvidia: Potential H200 Shipments to China in the Spotlight